These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

65 related items for PubMed ID: 3037448

  • 1. Hypocalcaemic effect of WR-2721, S-2 (3-aminopropylamino) ethyl-phosphorothioic acid in an anuric haemodialysis patient.
    Zingraff J, Bourdeau A, Clair F, Kindermans C, Buisson C, Manganella G, Sachs C, Drüeke T.
    Nephrol Dial Transplant; 1987; 2(1):48-52. PubMed ID: 3037448
    [Abstract] [Full Text] [Related]

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 3. Normalization of hypercalcemia associated with a decrease in renal calcium reabsorption in Leydig cell tumor-bearing rats treated with WR-2721.
    Hirschel-Scholz S, Caverzasio J, Rizzoli R, Bonjour JP.
    J Clin Invest; 1986 Jul; 78(1):319-22. PubMed ID: 3013941
    [Abstract] [Full Text] [Related]

  • 4. Treatment of hypercalcemia in parathyroid cancer with WR-2721, S-2-(3-aminopropylamino)ethyl-phosphorothioic acid.
    Glover DJ, Shaw L, Glick JH, Slatopolsky E, Weiler C, Attie M, Goldfarb S.
    Ann Intern Med; 1985 Jul; 103(1):55-7. PubMed ID: 2988391
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of parathyroid hormone secretion and parathyroid hormone-independent diminution of tubular calcium reabsorption by WR-2721, a unique hypocalcemic agent.
    Hirschel-Scholz S, Caverzasio J, Bonjour JP.
    J Clin Invest; 1985 Nov; 76(5):1851-6. PubMed ID: 2997292
    [Abstract] [Full Text] [Related]

  • 6. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.
    Am J Nephrol; 2008 Nov; 28(1):97-106. PubMed ID: 17914251
    [Abstract] [Full Text] [Related]

  • 7. Interference of WR-2721 with magnesium metabolism: mechanism of action.
    Hirschel-Scholz S, Paunier L, Bonjour JP.
    Miner Electrolyte Metab; 1988 Nov; 14(2-3):114-20. PubMed ID: 2837628
    [Abstract] [Full Text] [Related]

  • 8. Suppression of parathyroid secretion after administration of WR-2721 in a patient with parathyroid carcinoma.
    Hirschel-Scholz S, Jung A, Fischer JA, Trechsel U, Bonjour JP.
    Clin Endocrinol (Oxf); 1985 Sep; 23(3):313-8. PubMed ID: 3000652
    [Abstract] [Full Text] [Related]

  • 9. Intravenous 1,25(OH)2D therapy increases the intact parathyroid hormone secretion set point in hemodialyzed patients.
    Brossard JH, Roy L, Lepage R, Gascon-Barré M, D'Amour P.
    Miner Electrolyte Metab; 1997 Sep; 23(1):25-32. PubMed ID: 9058366
    [Abstract] [Full Text] [Related]

  • 10. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R, Herman A, Ferreira C, Travassos F, Nunes-Azevedo J, Oliveira M.
    Nefrologia; 2002 Sep; 22(5):448-55. PubMed ID: 12497746
    [Abstract] [Full Text] [Related]

  • 11. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
    Lindberg J, Martin KJ, González EA, Acchiardo SR, Valdin JR, Soltanek C.
    Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662
    [Abstract] [Full Text] [Related]

  • 12. Clodronate in the medical management of hyperparathyroidism.
    Hamdy NA, Gray RE, McCloskey E, Galloway J, Rattenbury JM, Brown CB, Kanis JA.
    Bone; 1987 Oct; 8 Suppl 1():S69-77. PubMed ID: 2961358
    [Abstract] [Full Text] [Related]

  • 13. S-2-(3-Aminopropylamino)ethyl phosphorothioic acid (WR-2721) in primary hyperparathyroidism.
    Morita M, Higashi K, Tajiri J, Sato T.
    Ann Intern Med; 1985 Dec; 103(6 ( Pt 1)):961. PubMed ID: 2998254
    [No Abstract] [Full Text] [Related]

  • 14. Effect of calcium and 1,25 dihydroxyvitamin D on the level of parathyroid hormone in patients with secondary hyperparathyroidism due to chronic renal insufficiency.
    Vucković S, Paunković N.
    Med Pregl; 1993 Dec; 46 Suppl 1():40-2. PubMed ID: 8569602
    [Abstract] [Full Text] [Related]

  • 15. Treatment of secondary hyperparathyroidism of predialysis chronic renal failure with low doses of 1,25(OH)2D3: humoral and histomorphometric results.
    Coen G, Mazzaferro S, Bonucci E, Ballanti P, Massimetti C, Donato G, Landi A, Smacchi A, Della Rocca C, Cinotti GA.
    Miner Electrolyte Metab; 1986 Dec; 12(5-6):375-82. PubMed ID: 3492662
    [Abstract] [Full Text] [Related]

  • 16. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.
    Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM.
    Am J Kidney Dis; 2006 Feb; 47(2):263-76. PubMed ID: 16431255
    [Abstract] [Full Text] [Related]

  • 17. In vivo and in vitro effects of WR-2721 in experimental hypercalcemia in the rat.
    Weiss J, Walker ST, Fallon M, Goldfarb S.
    J Pharmacol Exp Ther; 1986 Sep; 238(3):969-73. PubMed ID: 3018229
    [Abstract] [Full Text] [Related]

  • 18. Frequent recurrence of secondary hyperparathyroidism after pulse oral calcitriol withdrawal in PD patients.
    Bajo MA, Selgas R, Possante C, Aguilera A, Sánchez C, Diaz C, de Alvaro F, Martinez ME.
    Adv Perit Dial; 1997 Sep; 13():239-43. PubMed ID: 9360690
    [Abstract] [Full Text] [Related]

  • 19. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis.
    Goldenberg MM.
    Clin Ther; 1999 Mar; 21(3):432-41. PubMed ID: 10321413
    [Abstract] [Full Text] [Related]

  • 20. Severe hyperparathyroidism despite paricalcitol therapy: one-year follow-up.
    Shuja SB, Raja RM.
    Adv Perit Dial; 2003 Mar; 19():231-5. PubMed ID: 14763069
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.